Home › Funds › ExodusPoint Capital Management, LP › BBIO

ExodusPoint Capital Management, LP position in BBIO

BRIDGEBIO PHARMA INC · Health Care

ExodusPoint Capital Management, LP reported holding 45,500,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$70.9M, representing 0.60% of its reported portfolio and ranking #16 among its reported holdings. ExodusPoint Capital Management, LP has disclosed BBIO holdings in 7 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)45.50M sh
Reported value held$70.85M
Portfolio Weight0.60%
First reportedQ2 2024
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How ExodusPoint Capital Management, LP's BBIO position evolved

ExodusPoint Capital Management, LP first disclosed a stake in BBIO in Q2 2024 at 14,890 shares (US$377K). The position peaked in Q3 2026 at 45,500,000 shares, worth US$70.9M. Across 7 filings, ExodusPoint Capital Management, LP increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 45,500,000 shares valued at US$70.9M — an increase of 45,275,073 shares quarter over quarter.. Notable position changes include a 439% increase in Q2 2025 (shares rose 20% over the following quarter), a 312% increase in Q4 2025 (shares fell 3% over the following quarter), a 20129% increase in Q3 2026 (shares rose 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 14.89K $377.00K New
Q1 2025 35.38K $1.22M New
Q2 2025 190.57K $8.23M Add
Q3 2025 30.43K $1.58M Reduce
Q4 2025 125.30K $9.58M Add
Q2 2026 224.93K $16.75M New
Q3 2026 45.50M $70.85M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 41 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has ExodusPoint Capital Management, LP held BBIO?

ExodusPoint Capital Management, LP has disclosed BBIO holdings in 7 of the last 10 reported quarters, going back to Q2 2024.

What is ExodusPoint Capital Management, LP's current position in BBIO?

As of Q3 2026, ExodusPoint Capital Management, LP holds 45.50M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $70.85M, representing 0.60% of its reported portfolio and ranking #16.

Has ExodusPoint Capital Management, LP been buying or selling BBIO?

In the latest 13F filing (Q3 2026), ExodusPoint Capital Management, LP increased its position in BBIO. The position peaked in Q3 2026 at 45.50M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, FARALLON CAPITAL MANAGEMENT, L.L.C., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.